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1. Introduction 
In the 16th century, Leonardo Da Vinci had described “the narrowing of the passage of blood 
vessels, thickening of the coats of these vessels and hardening of arteries” in his work (Boon, 
2009). This is the first known documentation of atherosclerosis (AS). Today, our 
understanding of atherogenesis as a process of a chronic inflammatory disease has been 
greatly promoted by many theories, such as, the cellular cycle of cholesterol and 
hypercholesterolemia, dysfunction of endothelial cells, oxidized lipoproteins, discovery of 
scavenger receptors and response to injury theory, among others. The factors leading to the 
elucidation of atherogenesis are still not all known, since AS can persist silently 
(subclinically) without showing any serious symptoms for a longer period. That, together 
with the fact that AS is not limited to warm-blooded vertebrates and the occurrence of 
intimal thickening of coronary arteries in rabbitfish (Duran et al., 2010), as well as evidence 
of coronary AS in salmonids (Farrell, 2002), brings proof that AS is still a largely elusive, 
complicated and multi-component disease.  
AS is not a modern world disease as determined by recent images obtained from coronary 
arteries and the aorta of ancient mummies. Atheromatous lesions, as well as aortic AS were 
identified in an Aleutian mummy from Alaska originating from 400 AD (Zimmerman, 
1998). In 2009, images generated by computer tomography of vascular calcifications in 
examined Egyptian mummies found that 16 out of the 22 examined mummies had 
identifiable cardiovascular tissue, with definite AS present in 5 and AS found in additional 4 
mummies (together 56% of total) (Allam et al., 2009). This study was recently expanded to 
52 ancient Egyptian mummies from the Middle Kingdom to the Greco-Roman period and 
identified cardiovascular structures in 44 mummies, with 20 of these showing either definite 
AS (n=12, as defined by calcification within the wall of an identifiable artery) or probable AS 
(n=8, as defined by calcifications along the expected course of an artery) (Allam et al., 2011). 
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The calcifications were located in the aorta, as well as coronary, carotid, iliac, femoral and 
peripheral arteries. The 20 mummies with definite and probable AS were significantly older 
at time of death (mean age 45.1 ± 9.2 years) as compared to mummies that had 
cardiovascular tissue identified without AS (mean age 34.5 ± 11.8 years). Since social status 
(mummies were usually of higher status, than others in the population), diet (mainly 
wildlife and grains) and tobacco (not yet known) were not risk factors in the life of ancient 
Egyptians, they could not contribute to the development of AS in this population. Age, 
however has been re-affirmed with these studies, as one of the most important independent 
systemic risk factors for AS. 
2. Brief clinical characterization of the disease 
AS is a chronic, multifocal immunoinflammatory, fibroproliferative disease and is the most 
common form of arteriosclerosis. AS is a disease of the arterial wall, which often starts in 
young people. In middle-aged individuals, AS can start to appear in clinically recognizable 
forms, such as coronary artery disease (CAD), cerebral vascular or peripheral artery disease. 
It can affect all large and medium-sized arteries including the coronary, carotid, cerebral 
arteries, the aorta, its branches and main arteries of the extremities. Areas of non-laminar 
blood flow are highly susceptible to plaque formation.  
The clinical endpoints of AS may result as a consequence of several mechanisms, such as:  
1. artery-to-artery embolism of thrombus formed on an atherosclerotic plaque, 
2. atheroembolism of cholesterol crystals or other atheromatous debris, 
3. acute thrombotic occlusion resulting from plaque rupture, 
4. structural disintegration of the arterial wall resulting from dissection or subintimal 
hematoma, and 
5. reduced perfusion resulting from critical stenosis or occlusion caused by progressive 
plaque growth 
Ultrasound is one of the most commonly used noninvasive examinations for assessment of 
early and advanced atherosclerotic vascular changes, also of the carotid intima media 
thickness. However, ultrasound has limited diagnostic and prognostic value, and for pre-
operative procedures, arteriographies and other methods of the involved vessels are 
necessary. 
AS is considered to be the leading cause of death and loss of disability adjusted life-years 
worldwide, particularly in the developed countries, according to United States Statistical 
Update from 2011 (Roger et al., 2011). CAD accounted for  1 of every 6 deaths and stroke  
1 of 18 deaths in 2007. Recently, peripheral artery disease was reported to be present in 12% 
of United States citizens (Beers et al., 2006). 
3. Inflammation and the involvement of cells/molecules in atherosclerosis 
Inflammation contributes to the formation and progression of AS (Libby, 2002; Moubayed et 
al., 2007). Since AS represents a chronic inflammatory state, levels of C-reactive protein 
(CRP) are important, and were found to be an independent predictor of cardiovascular 
disease (CVD) (Fruchart et al., 2004), although other studies have not been able to confirm 
this (Kullo & Ballantyne, 2005). Serum amyloid A (SAA) has been reported to also play a 
role in atherosclerosis (King et al., 2011) which has been supported by animal models (Chait 
et al., 2005; Hua et al., 2009; Malle & De Beer, 1996). In human primary coronary artery 
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endothelial cells, SAA was reported to induce the release of interleukin-6 (IL-6), IL-8 and 
stimulate the expression and release of soluble intercellular adhesion molecule (sICAM) and 
soluble vascular adhesion molecule (sVCAM), as well as E-selectin synthesis. The data 
indicated greater susceptibility of coronary artery endothelial cells (in comparison to human 
umbilical vein endothelial cells) to SAA (Lakota et al., 2007) which indicated the potential 
role of SAA in CAD. Studies for fibrinogen consistently link this factor, which is involved in 
both inflammation and thrombosis, with AS burden and risk of coronary heart disease 
(CHD) (Kullo & Ballantyne, 2005). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a 
novel biomarker of vascular-specific inflammation providing information about 
atherosclerotic plaque inflammation and stability. Elevated levels of serum Lp-PLA2 are 
indicative of rupture-prone plaques and a strong independent predictor of cardiovascular 
risk (Colley et al., 2011). Most recently, Herder et al. reported on biomarkers associated with 
prediction of incident coronary events (Herder, Karakas, et al., 2011). The group mentioned 
the following markers: IL-6, IL-8, IL-18, macrophage migration inhibitory factor (MIF), 
monocyte chemotactic protein-1, interferon-┛ inducible protein-10, transforming growth 
factor-┚1 (TGF-┚1), sE-selectin and sICAM (Herder, Baumert, et al., 2011). The data showed 
that the combination of blood biomarkers could improve the prediction of cardiovascular 
outcome above the traditional ones used. 
Some infectious diseases represent an independent initiator of vascular inflammation which 
can contribute to atherogenesis and progression of AS. Bacteria and viruses can upregulate 
cytokines, chemokines and acute phase reactants, such as CRP and SAA, which lead to 
endothelial dysfunction. Overall, expression of Toll-like receptors in the atheroma, mouse 
model experiments and the role of genetic polymorphisms, all currently suggest microbe 
activation of inflammation in plaques and AS progression (Vallejo, 2011). Infection is also 
known to convert a lipidogenic profile into a pro-atherogenic one (Khovidhunkit et al., 
2000).  
Infections important in association with AS were shown in many studies and include the 
following infectious agents Herpes virus, C. pneumonie, P. gingivitis, H. pylori, among others 
(Kowalski et al., 2006; Ludewig et al., 2004; Ross, 1999). There was also presence of bacterial 
antigens reported in atheroma (Ott et al., 2006). The latter finding raises the question of single 
antigen importance versus total infectious burden in accelerating AS (Gabrielli et al., 2002).  
Presence of antibodies against infectious agents represent a risk factor for CVD. In terms of 
specific antigen involvement in AS, the following (among others) have been reported: H.pylori 
heat shock protein (HSP)-60 elicited antibodies can crossreact with endogenous molecules, 
stress-related endothelial HSP-60 and the presence of HSP-60-specific T lymphocytes in the 
circulation, may increase the risk of AS (Ayada et al., 2007). Occurrence of antiphospholipid 
antibodies after certain infections is also common and can lead to initial endothelial 
dysfunction (Altman, 2003). Latency and intracellular infection importance stays an open 
ended question (especially in C.pneumonie, Cytomegalovirus). Long term effects of infections on 
AS progression are unclear, however statistics show undoubtedly more cases of stroke and 
myocardial infarction in the first 3 days following an acute urinary/respiratory infection with 
declining numbers in following weeks (Graham et al., 2007).  
A unifying view of the pathophysiology of AS proposes that inflammation has a key role by 
transducing the effects of many known risk factors of the disease. Although the combined 
experimental and clinical evidence may convince some, the chicken and egg problem about 
causality, remains unsolved (Libby et al., 2011). 
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3.1 Initial injury 
Endothelial cells provide a physical barrier layer between the circulatory system and the 
intima, however the cells also actively synthesize molecules responsible for the maintenance 
of circulatory homeostasis and participate in plaque development. 
The initial process in the development of AS is isolated endothelium injury and subsequent 
endothelial activation followed by expression of different pro-inflammatory cytokines, 
chemokines and adhesive molecules resulting in monocyte attraction, the rolling mechanism 
and their migration into the tunica intima (Jan et al., 2010; Ross, 1999). Monocytes transform 
into macrophages, the activation of which leads to the hallmark of plaque development or 
foam cell formation. An important molecule in this process is oxidized low density 
lipoproteins (oxLDL), which originates from retained LDLs in the tunica intima. Molecules 
of oxLDL and their binding to scavanger receptors on macrophages stimulates the 
accumulation of lipids in the cells and the formation of foam cells (Hansson, 2005).  
When inflammatory cells (such as leukocytes, monocytes and macrophages) migrating into the 
intima, start to accumulate subendothelial lipid, particularly oxidized lipid, this exacerbates 
the initial, local inflammatory reaction and maintains activation of the overlying endothelium. 
This results in continued expression of adhesion molecules and pro-inflammatory cytokines 
and chemokines perpetuating cell activation. Normally, the endothelium shows anti-adhesive, 
anti-thrombotic and vasoregulatory properties. Thus, stress conditions, mechanical damage or 
patho-physiological stimulation can cause modified endothelial cell characteristics (Stoltz et 
al., 2007). Endothelial injury can be different based on the different original vascular beds the 
cells arise from. Their physiological roles in coagulation, hemodynamics and susceptibility to 
patho-physiological stimuli can also differ depending on the vascular bed origin and the 
influence of the microenviroment (Aird, 2007; Cines et al., 1998; Lacorre et al., 2004; Luu et al., 
2010; Yano et al., 2007). For example, differences in endothelial cell responses were described 
for activation with tumour necrosis factor  (TNF-) (Lehle et al., 2007; Methe et al., 2007; 
Viemann et al., 2006), SAA and IL-1┚ (Lakota et al., 2007; Lakota et al., 2009) and oxLDL (Deng 
et al., 2006). Recently, endothelial damage has been reported as being able to be repaired with 
endothelial progenitor cells (Bai et al., 2010).  
Endothelial cells seem to be involved prevalently in the earlier stages of atherogenesis, 
leading to initial vascular injury, as well as in later stages, when they detach in response to 
injury and enter the circulation. Circulating endothelial cells can be used as a marker of 
vascular injury. Their number increase is associated with CVD, as well as they can serve as 
an accurate predictor of major adverse events following myocardial infarction. They also 
inversely correlate with flow-mediated dilatation and positively correlate with markers of 
endothelial injury (such as von Willebrand factor, tissue plasminogen activator inhibitor, E-
selectin) and prothombotic state (tissue factor). They are rarely found in healthy individuals, 
but are increased and correlate with disease activity in different vasculitides, in systemic 
lupus erythematosus (SLE) and systemic sclerosis (SSc) (Boos et al., 2006). Interestingly, 
Mutin et al. showed increased circulating endothelial cells in acute myocardial infarction 
and unstable angina without increased levels of markers of activation (ICAM, VCAM, E- 
selectin) and no apoptosis (Mutin et al., 1999).  
3.2 Progression of atherosclerotic plaques 
Early atherosclerotic lesions called fatty streaks involve a growing extracellular lipid core 
within the atherosclerotic plaques. The next stage of atherosclerotic plaque formation 
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involves the proliferation and migration of smooth muscle cells into the tunica intima, 
accumulation of collagen and fibrous cap formation (Hansson, 2005; Libby, 2002). T 
lymphocytes with a prevailing Th1 response, together with smooth muscle cell proliferation 
and deposition of collagenous fibers contribute to the fibrous cap formation. Fibrosis and 
collagen accumulation have a patho-physiological parallel in other chronic inflammatory 
diseases such as rheumatoid arthritis (RA), cirrhosis and pulmonary fibrosis, among others, 
where monocytes and lymphocytes are also the active players. In later stages of AS plaque 
development, expression of proteases increases (i.e. matrix metalloproteinases (MMPs)) 
leading to degradation of collagen.  
During the development of AS plaques, monocyte-derived macrophages and T-
lymphocytes that invade evolving atherosclerotic lesions produce soluble inflammatory 
mediators (cytokines and chemokines) which are very important in the perpetuation of 
the disease. Certain cytokines and chemokines (i.e. IL-1, IL-12, IL-18, TNF- ┙, MIF, 
interferon-┛ (IFN-┛) , and granulocyte macrophage colony stimulating factor (GM-CSF) 
have explicit pro-atherogenic characteristics, others (i.e. IL-10 and probably IL-5) have 
anti-atherogenic properties, while IL-4, IL-6, and GM-CSF can have both pro- or anti-
atherogenic properties. Several of the pro-atherogenic cytokines affect plasma cholesterol 
levels, indicating that inflammation and lipid metabolism are interlinked processes in AS 
(Kleemann et al., 2008).  
Fatty streaks do not necessarily progress into advanced lesions. Certainly the progression of 
plaques is not linear (Figure 1) and depends largely on the microenvironment. Plaques can 
be clinically silent for years. Almost all adolescent children may already show some 
evidence of fatty streaks (Kumar et al., 2007).  
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Fig. 1. Simplified putative scheme of progression/regression of atherosclerosis at the 
cellular and molecular levels. MI, myocardial infarction; CVI, cerebrovascular insult 
Clinical prognosis is determined by the biological nature of the atherosclerotic plaque. 
Atheroma with active inflammatory processes are most prone to ruptures (Libby, 2002; 
Ross, 1999) and inflammation largely accounts for progression of stable to unstable angina 
(J.T. Wu & L.L. Wu, 2005). Rupture prone/unstable plaques are the ones with a large lipid 
core, many inflammatory cells and a thin fibrous cap (Gziut & Gil, 2008; Krone & Muller-
Wieland, 1999). 
There are three typical types of cellular/molecular influences of plaque rupture, among 
others:  
a. desquamation of the endothelium (due to proinflammatory mediators, MMPs, T cells 
which attack the basal membrane of the endothelium) which uncovers the collagen and 
thrombosis can occur. Although desquamation is common and often asymptomatic it 
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accounts for ¼ of fatal coronary thromboses (Libby, 2002). Mast cells contribute to 
endothelial erosions by releasing proteases that degrade cadherin and fibronectin 
(Mayranpaa et al., 2006) 
b. disruption of neo-angiogenic blood vessels, growing in the atheroma full of growth 
factors. This leads to thrombin activation, collagen expression and smooth muscle cell 
proliferation (Libby, 2002) 
c. fibrous cap rupture is the most common of plaque rupture and is due to inflammation 
in the lipid core, MMPs and tissue factor release from plaques. TGF-┚ and vascular 
endothelial growth factor released for the purpose of wound healing of the ruptures 
causes additional fibroses which narrow further the lumen of the vessel and can cause 
ischemia. 
Major clinical complications and subclinical events are presented in Figure 2. 
 
 
Fig. 2. Some clinical and subclinical atherosclerosis complications  
3.3 Regression of atherosclerotic plaques 
Previously, AS was thought to be reversible in early stages with changes of lifestyle and 
dietary modifications, as shown on animal models (J.J. Badimon et al., 1990; Malinow, 1983) 
and was believed to be reversible only to the stages before fatty streak formation. Currently, 
however, it is accepted that later stages can also be reversible as well. Some important 
regressions of even necrotic lesions and foam cell disappearance were achieved with 
injections of cholesterol-free phosphocholine liposomes which lower total cholesterol and 
mobilize cholesterol from plaques in animals (Williams et al., 2008). In regression of AS, 
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endothelium-dependent relaxation improves, as well as hypersensitivity of blood vessels, 
however maximal vasodilator activity/capacity does not improve (presumably due to 
fibrosis of arteries) (Heistad et al., 1990).  
There are some problems occurring with evaluating the extent of AS, as well as in 
extrapolating animal studies to humans (Vilahur et al., 2011). The evaluation of AS 
regression presents a problem especially because the probability of cardiovascular events is 
stochastic and not only dependent on size of the plaque. Due to this, interpreting clinical 
studies in a manner of regression can also be difficult.  
4. Autoimmunity and atherogenesis  
Our understanding of AS has been crucially changed from a simply degenerative disorder 
to one that is a complex, inflammatory and autoimmune disease, in which all branches of 
immune system are involved. The role of autoimmunity has been shown in clinical and 
experimental models. Active immunization with HSP-60 or ┚2-GPI induces autoantibodies 
and accelerates AS. The transfer of lymphocytes from ┚2-GPI-immunized mice to other mice 
resulted in advanced AS (Sherer & Shoenfeld, 2006).  
The AS process may be magnified and accelerated in patients with autoimmune diseases. 
Autoimmunity-related risk factors according to Bijl et al. include the presence of anti-
cardiolipid antibodies (aCL), antibodies against oxLDL, antibodies against endothelial cells, 
antibodies against neutrophil cytoplasm antigens, antibodies against ribonuclear proteins 
and antibodies against lipoprotein lipase (Bijl, 2003). Additional risk factors recorded by 
Ronda and Meroni included anti-HSP-60/70 antibodies and anti-┚2-glycoprotein (┚2-GPI) 
antibodies (Ronda & Meroni, 2008). It must be pointed out however, that HSP-70 antigen 
itself is protective for AS (Frostegard, 2005).  
The acceleration of AS in patients with autoimmune disease is due to the underlying 
immune system dysfunction, the presence of systemic inflammation and endothelial 
activation with the effects of chronic therapies (Ronda & Meroni, 2008). Accelerated and 
premature AS is associated specifically with autoimmune rheumatic diseases of 
inflammatory nature, most markedly with SLE (Roman et al., 2003; Salmon & Roman, 2008) 
and antiphospholipid syndrome (APS) (Jara et al., 2007), but also with RA (Salmon & 
Roman, 2008) and SSc (Shoenfeld et al., 2005), certain forms of vasculitis (Shoenfeld et al., 
2005) and Sjogren’s Syndrome (Gerli et al., 2010; Vaudo et al., 2005). For SSc however, the 
data are still inconsistent (Zinger et al., 2009).  
Many components of the immune system are involved in AS and all arms of the immune 
system are engaged in atherogenesis with different cells (such as monocytes, 
macrophages, T lymphocytes) and different molecules involving both the cellular and 
humoral, innate and adaptive immunity. Certain important mechanisms for AS in 
autoimmune diseases are proposed below. One of them postulates that pre-existing 
adaptive and innate immunity involving HSP-60 exposed on the arterial endothelial cells 
could lead to the development of an initial inflammatory stage of atherogenesis. The 
progress of AS depends on the expression and accessibility of atherogenic HSP-60 
epitopes on endothelial cells. Since low level of autoimmunity to HSP-60 is evolutionary 
present in all individuals, the development of AS depends mainly or even exclusively, on 
the condition of the endothelial cells (Wick & et al., 2006). ┚2-GPI is another autoantigen 
expressed within subendothelial regions and intimal-medial border of human 
atherosclerotic plagues, suggested to be involved in atherogenesis. It is targeted by anti-
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┚2-GPI antibodies, which results in increased amounts of colocalized CD4+ lymphocytes 
in the endothelia (Ronda & Meroni, 2008; Shoenfeld et al., 2001). These antibodies can also 
induce a pro-inflammatory and procoagulant phenotype (Harats & George, 2001).  ┚2-GPI 
can also form complexes with oxLDL, which stimulate the immune system to produce 
autoantibodies to these oxLDL/┚2-GPI complexes. Such immune complexes are uptaken 
by macrophages. Complexes, together with autoantibodies, have been described in 
patients with SLE and/or APS, indicating another mechanism of accelerated AS in 
patients with underlaying autoimmune disease (Matsuura et al., 2009). Further data is 
emerging that IgG anti-oxLDL/┚2-GPI antibodies have been associated with pro-
atherogenic functions, whereas IgM anti-oxLDL/┚2-GPI have been considered to be anti-
atherogenic (Narshi et al., 2011). In our recent study of 70 RA female patients, which were 
followed for 5.5 years, neither antibodies against ┚2-GPI, nor rheumatoid factor or CRP 
contributed to AS progression, as measured by carotid intima media thickness and 
number of plaques (Holc et al., 2011). 
The increased risk of AS in patients with autoimmune rheumatic diseases is explained only 
in part by traditional AS risk factors, such as those from the Framingham study (Lloyd-Jones 
et al., 2004; Tegos et al., 2001), for example autoimmune patients commonly have 
dislipidemias. The process of inflammation (as a nontraditional risk factor) can aggravate 
atherosclerosis via different mechanisms secondary to autoimmunity and infectious 
diseases. Increased levels or presence of inflammatory markers: CRP, SAA, fibrinogen, IL-6, 
cluster differentiation markers CD40/CD40L and adhesion molecules have been reported 
(Shoenfeld et al., 2005).  
Peroxidation of LDLs is low in the blood, but is extensive in the intima. Oxygen radicals and 
oxidizing enzymes modify proteins and lipids of the LDL, which activate endothelial cells to 
express vascular cell adhesion molecules (L. Badimon et al., 2011). OxLDL is a target of the 
immune system resulting in the production of autoantibodies (R. Wu & Lefvert, 1995), 
which could be, on one hand, an enhancer of oxLDL uptake by macrophages, inflammation 
and atherogenesis (Ronda & Meroni, 2008) or, on the other hand, may contribute to oxLDL 
clearance in healthy persons (Cerne et al., 2002). Antibodies against HDL have also been 
implicated in AS. Cross-reactivity is thought to exist between aCL, anti-HDL and anti-
ApoA-I IgG antibodies in patients with SLE and primary APS and can lead to the 
diminishing HDL’s protective role (Delgado Alves et al., 2003; Shoenfeld et al., 2005; Tincani 
et al., 2006). 
A representative compilation of autoimmune diseases with accelerated AS is provided 
below (Figure 3). 
Possible risk factors for AS in autoimmune diseases also represent frequently 
accompanying renal involvement. Questions were raised if plaques are more prone to 
rupture due to the fact that they are also qualitatively different in autoimmune diseases. 
Since systemic autoimmune disease patients are on drug therapy for life, there is a need to 
stress the influence of some common drugs. For instance, corticosteroids increase 
triglyceride levels, while methotrexate increases the levels of serum homocysteine 
(Frostegard, 2005). 
Vaccination represents an attractive approach to induce long–term protective immunity. 
Atherosclerosis was reduced by vaccination with oxLDL or HSP-60 in animal 
experiments (Hansson, 2005) that could be due to the induction of protective antibodies 
or T cells. 
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Fig. 3. Representative compilation of autoimmune diseases with accelerated AS with the 
processes and autoantibodies indicated. aCL, antibodies against cardiolipin; AECA, anti-
endothelial cell antibodies; ANCA, anti-neutrophil cytoplasmic antibodies; Anti-2-GPI, 
antibodies against 2-glycoprotein I; Anti-dsDNA, antibodies against double stranded 
DNA; Anti-HSP, antibodies against heat-shock protein antibodies; Anti-oxLDL, antibodies 
against oxidized LDL; Anti-oxLDL/2-GPI, antibodies against oxidized LDL/2-
glycoprotein I complexes; RF, rheumatoid factor; APS, antiphospholipid syndrome; RA, 
rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjogren’s syndrome; SSc, 
systemic sclerosis 
5. Antiinflammatory atheroprotective effects and therapies in atherosclerosis  
A growing body of evidence indicates that inflammation not only provides the baseline for 
future atherosclerotic events, but is a necessity for coronary plaque formation. The unique 
responsiveness of human coronary artery endothelial cells could account for the greater 
susceptibility of coronary arteries to inflammation and atherogenesis leading to 
cardiovascular pathology. Both black tea extract and resveratrol have been shown to 
significantly inhibit IL-1β-induced IL-6 and tissue factor expression and activity responses in 
human coronary artery endothelial cells (Lakota et al.., 2009).  
The downregulation of TNF-alpha induced by skeletal muscle derived IL-6 may also 
participate in mediating the atheroprotective effect of physical activity (Szostak & Laurant, 
2011).  
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Powerful anti-inflammatory agents could represent treatments for acute coronary syndrome 
(Hansson, 2005; Libby, 2002; Nilsson et al., 2005). Eicosanoid-modulating anti-inflammatory 
compounds, such as the cyclooxygenase-2 inhibitor rofecoxib are inappropriate in patients 
with CVD, since enzymes inhibited by them, are important in both the production of pro- 
and anti-thrombotic eicosanoids, depending on the cells effected. Lipid-lowering statins also 
have anti-inflammatory properties, likely stemming from the ability of statins to inhibit the 
formation of mevalonic acid, effecting cholesterol, as well as several isoprenoid 
intermediates used by lipids to attach to different intracellular signaling molecules. In 
certain studies, the reduction of inflammation (reflected by CRP levels) through statin 
therapy improved the clinical outcome of CAD, independently of the reduction in serum 
cholesterol levels (Hansson, 2005). 
When macrophages are appropriately activated they can secrete anti-inflammatory 
cytokines and synthesize matrix repair proteins that stabilize vulnerable plaques (Wilson, 
2010). There are also many results from mice studies which show that modulating the 
activity of selected cytokines (either systemically or locally) can prevent or retard the 
development of atherosclerotic lesions and could significantly contribute to early detection 
and treatment of AS or in combination with established hypolipidaemic and 
antihypertensive treatment. The activity of the cytokines of interest can be modulated by 
different techniques such as genetic deletion, overexpression, immunoneutralization, or in 
vivo administration of the cytokines or their receptors or inhibitors (Kleemann et al., 2008). 
Chlamydia pneumoniae (Cp) infection has been associated with AS, and beneficial effects of 
antibiotic therapy on future cardiovascular events have been described. For example, a 
dramatic reduction in endpoints (cardiovascular death, hospital admission with unstable 
angina or acute myocardial infarction or need for revascularization) in a small number of 
high risk patients with CAD suggested the potential of azithromycin therapy in preventing 
future acute cardiac events (Mehta et al., 1998). The reduced intima media thickness 
progression after roxithromycin therapy in Cp seropositivity may be explained by several 
beneficial effects of antibiotic treatment on atherosclerotic plaque formation, such as those 
attributable to a reduced smooth muscle cell proliferation or a decreased smooth muscle cell 
migration from the media and adventitia into the intima, a reduced lipid accumulation, an 
improvement of endothelial function, and diminished inflammatory activity (Sander et al., 
2002). The group reported a significant reduction of CRP in the Cp-positive group of 
patients with ischemic stroke treated with roxithromycin in a two year follow-up study. In 
contrast, there was no significant change of CRP in the placebo-treated Cp-positive group. 
Reductions in CRP and other inflammatory markers were also observed in previous 
antibiotic trials (Gurfinkel et al., 1999; Muhlestein et al., 2000). 
6. Conclusion 
Taken together, AS is a complex, multi-component, inflammatory, as well as autoimmune 
disease. Balancing pro- and anti-inflammatory mediators, destructive and protective 
antibodies can be one approach to maintaining homeostasis. Serum markers of 
inflammation have emerged as an important component of cardiovascular risk factor 
burden. On the other hand, some current reports indicate that detection of novel 
inflammatory marker levels (i.e. using microchips or multi-marker panels) are adding only 
minimally to the ability of traditional risk factors to predict cardiovascular outcome. 
However, discovering novel detection methods for different types of markers may be a way 
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to help clinicians in identifying/clarifying which patients are at borderline risk and require 
drug therapy earlier. Fine-tuning the stage of disease progression using appropriate 
medication can lead to AS regression. Clinicians need more information to support their 
optimal judgment in this crucial decision-making process. Further directions suggest more 
predictive and personalized multi-marker medicine and appropriate earlier risk 
intervention. In addition, more preventive care and participatory feedback are necessary. 
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